CNO Financial Group, Inc. (CNO) Is At $24.87 Formed Wedge; Sucampo Pharmaceuticals (SCMP) Has 1.65 Sentiment

Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing, identifying, acquiring, and marketing medicines that meet unmet medical needs, primarily in gastroenterology, ophthalmology, and oncology-related disorders in the United States, Japan, Switzerland, and internationally. The company has market cap of $788.97 million. The companyÂ’s marketed product includes AMITIZA , a ClC-2 chloride channel activator for the treatment of chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation in adult women (IBS-C), and opioid-induced constipation (OIC)in patients with chronic non-cancer related pain; and RESCULA (unoprostone isopropyl), a big potassium channel activator for the treatment of glaucoma and ocular hypertension. It currently has negative earnings. The Company’s product candidates in clinical development stage comprise Lubiprostone that is in Phase III clinical trials for the treatment of pediatric functional constipation and (IBS-C); and completed Phase III clinical trials for the treatment of (CIC) in adults, IBS-C in adult women, and OIC in patients with chronic non-cancer pain, as well as CPP-1X/sulindac combination product, which has completed Phase III clinical trials for the treatment of familial adenomatous polyposis.

CNO Financial Group, Inc. (CNO) formed wedge up with $25.62 target or 3.00% above today’s $24.87 share price. CNO Financial Group, Inc. (CNO) has $4.17B valuation. The stock increased 1.14% or $0.28 during the last trading session, reaching $24.87. About 559,064 shares traded. CNO Financial Group, Inc. (NYSE:CNO) has risen 4.81% since December 24, 2016 and is uptrending. It has underperformed by 11.89% the S&P500.

Analysts await Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) to report earnings on March, 14. They expect $0.34 EPS, down 50.00% or $0.34 from last year’s $0.68 per share. SCMP’s profit will be $15.78M for 12.50 P/E if the $0.34 EPS becomes a reality. After $0.27 actual EPS reported by Sucampo Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 25.93% EPS growth.

Krensavage Asset Management Llc holds 10.42% of its portfolio in Sucampo Pharmaceuticals, Inc. for 2.83 million shares. Piermont Capital Management Inc. owns 178,570 shares or 0.7% of their US portfolio. Moreover, Malaga Cove Capital Llc has 0.58% invested in the company for 84,241 shares. The New York-based Clark Estates Inc Ny has invested 0.53% in the stock. Nea Management Company Llc, a Maryland-based fund reported 1.26 million shares.

The stock increased 0.29% or $0.05 during the last trading session, reaching $17. About 1.13 million shares traded. Sucampo Pharmaceuticals, Inc. (SCMP) has declined 5.30% since December 24, 2016 and is downtrending. It has underperformed by 22.00% the S&P500.

Since January 1, 0001, it had 0 insider purchases, and 3 insider sales for $24.83 million activity.

Ratings analysis reveals 67% of Sucampo Pharma’s analysts are positive. Out of 3 Wall Street analysts rating Sucampo Pharma, 2 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $16.0 while the high is $19.0. The stock’s average target of $17.50 is 2.94% above today’s ($17) share price. SCMP was included in 3 notes of analysts from September 7, 2016. The stock of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has “Outperform” rating given on Wednesday, September 7 by Northland Capital. The stock of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) earned “Buy” rating by Maxim Group on Tuesday, November 15. The firm has “Neutral” rating by Mizuho given on Monday, November 14.

Among 10 analysts covering CNO Financial Group (NYSE:CNO), 3 have Buy rating, 1 Sell and 6 Hold. Therefore 30% are positive. CNO Financial Group had 22 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Market Perform” rating by Wood given on Tuesday, August 2. On Monday, August 14 the stock rating was downgraded by Morgan Stanley to “Underweight”. The rating was maintained by Wells Fargo on Wednesday, July 26 with “Hold”. The rating was initiated by Raymond James with “Outperform” on Tuesday, December 22. On Tuesday, August 25 the stock rating was maintained by BTIG Research with “Buy”. The firm has “Outperform” rating by Wells Fargo given on Friday, September 23. The firm has “Hold” rating by Keefe Bruyette & Woods given on Thursday, August 31. Keefe Bruyette & Woods downgraded CNO Financial Group, Inc. (NYSE:CNO) on Wednesday, November 4 to “Market Perform” rating. Deutsche Bank maintained CNO Financial Group, Inc. (NYSE:CNO) rating on Monday, May 2. Deutsche Bank has “Hold” rating and $20 target. The company was initiated on Monday, January 25 by Deutsche Bank.

Analysts await CNO Financial Group, Inc. (NYSE:CNO) to report earnings on February, 6. They expect $0.41 earnings per share, up 17.14% or $0.06 from last year’s $0.35 per share. CNO’s profit will be $68.78M for 15.16 P/E if the $0.41 EPS becomes a reality. After $0.45 actual earnings per share reported by CNO Financial Group, Inc. for the previous quarter, Wall Street now forecasts -8.89% negative EPS growth.